文献速递瓣膜外科

女性经导管与外科主动脉瓣置换五年结局:系统评价与荟萃分析

Five-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Women: A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该系统评价与荟萃分析纳入6项RCT共3094例女性(TAVR 1587例、SAVR 1507例),比较5年全因死亡或致残性卒中的复合终点。

要点

  • 女性TAVR与SAVR的5年全因死亡或致残性卒中复合终点无显著差异。
  • 女性TAVR的1年优势未延续至5年,长期决策需权衡两者风险获益。
  • 未来研究应报告性别分层的主要和次要结局以指导个体化治疗。

研究设计与样本

  • 系统评价与荟萃分析,纳入6项比较TAVR与SAVR且完成5年随访的RCT,共3094例女性(TAVR 1587例、SAVR 1507例)。
  • 研究方案注册于PROSPERO(CRD420251004394),采用随机效应和固定效应模型进行荟萃分析。

主要发现

  • Meta回归未发现关键临床协变量与主要终点之间存在关联。
  • 试验序贯分析显示提取样本量达到所需信息量,但未确认确定性治疗效果。

临床怎么用

  • 女性主动脉瓣狭窄患者选择TAVR或SAVR时,应告知5年死亡或致残性卒中风险相似。
  • 不应仅基于1年随访的TAVR优势做长期决策,需综合评估个体风险获益。

局限性

  • 试验序贯分析未确认确定性治疗效果,长期结局仍需进一步研究。
  • 未来研究需性别分层报告主要和次要结局以全面评估风险获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Women patients with aortic stenosis (AS) exhibit distinct anatomic and physiologic features that may influence outcomes after valve replacement. While transcatheter aortic valve replacement (TAVR) has shown early advantages over surgical aortic valve replacement (SAVR) in women, long-term sex-specific outcomes remain unclear. To evaluate outcomes at 5 years comparing TAVR versus SAVR a systematic review and meta-analysis was performed. METHODS: A systematic literature review was conducted, identifying all randomized controlled trials (RCTs) comparing TAVR with SAVR which included women with completed 5-year follow-up. The primary outcome was the composite of all-cause mortality or disabling stroke. Meta-analysis was performed using both random-effects and fixed-effect models. The study protocol was registered in PROSPERO (CRD420251004394). RESULTS: Six RCTs were included with a total of 3094 women (1587 TAVR and 1507 SAVR). Overall, no significant difference was observed in the primary outcome between TAVR and SAVR (incidence rate ratios [IRRs] 1.00, 95% confidence interval [CI]: 0.88-1.13, P = .98). Meta-regression did not find any association between key clinical covariates and the primary outcome. Trial sequential analysis demonstrated that the extracted sample size met the required information size, but a definitive treatment effect was not confirmed. CONCLUSIONS: While TAVR shows an advantage over SAVR at 1-year follow-up in women, all-cause mortality or disabling stroke is similar in TAVR and SAVR at 5 years. Future studies must include sex-disaggregated reporting of both primary and secondary outcomes in order to comprehensively weigh risks and benefits of each intervention and inform personalized treatment strategies. CLINICAL REGISTRATION NUMBER: The study protocol was registered in PROSPERO (CRD420251004394).

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Wolf SEM, Kucera JA, Gregg AC, et al. Five-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Women: A Systematic Review and Meta-Analysis. Eur J Cardiothorac Surg. 2025. PMID: 41234051. doi:10.1093/ejcts/ezaf400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。